Hawaii may soon be more than just Paradise. It may also be a psychedelic therapy hub. A new state measure aims to legalize psilocybin, the hallucinogenic compound in certain mushrooms. The new bill was introduced by democratic Senators Stanley Chang, Laura Clint Acasio, Les Ihara Jr., and Maile Shimabukuro. If approved, Hawaii’s Department of Health would establish “designated treatment centers for the therapeutic administration of psilocybin and psilocyn.” The legislation would also remove the substances from the state’s list of Schedule 1 controlled substances. The proposed measure comes less than a year after the Aloha State saw legislation introduced to approve the study of psychedelic mushrooms. There are currently dozens of studies underway across the globe looking at psilocybin as a viable treatment option for a range of mental health issues. In particular, psilocybin is showing potential in treating patients diagnosed with treatment-resistant depression. If passed, the measure would also see the creation of a seven-person review panel aimed at assessing the policy change. The move comes on the heels of similar announcements by California and Florida legislators. Last November, voters in the nation’s capital and in Oregon decriminalized psychedelics. Oregon also became the first state to legalize psilocybin therapy. It now will develop standards for certifying therapists and treatment. Read more at: https://psychedelicspotlight.com/hawa…​ **Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing.

Similar Posts

Dr. Matthew Johnson discusses Psychedelics, the Hard Problem of Consciousness and UFOs

Dr. Matthew Johnson discusses Psychedelics, the Hard Problem of Consciousness and UFOs

Listen, Videos

During our time in Wonderland Miami, we had the pleasure to meet and interview Dr. Matthew Johnson of Johns Hopkins University. In this Psychedelic Spotlight Interview, we discuss a wide range of topics surrounding psychedelics and their effectiveness as treatments for ailments like tobacco addiction and PTSD. Of course, our conversation took as spin as we also touched on topics such as UFOs, DMT experiences and the CIA!

Timestamps:

0:00 – Intro
1:10 – Dr. Johnson’s latest updates on treating smoking cessation with psilocybin
6:55 – MAPS’ study using MDMA to treat PTSD
7:20 – DMT’S mystical experiences of perceiving aliens, machine elves and autonomous beings
13:08 – CIA research on psychedelics for telepathy and remote viewing
15:01 – What is consciousness?
19:02 – The intriguing evidence of UFOs?
21:40 – Where do we see psychedelics going in the next 5 years?

Make sure to like, share and subscribe if you enjoyed this episode!

#Psychedelics #MatthewJohnson #UFO

Interview with James Lanthier, CEO of Mindset Pharma

Interview with James Lanthier, CEO of Mindset Pharma

Interviews, Listen, Podcasts

In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.

MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)

MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)

Listen, Videos

MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!

In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.

As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.

Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?

Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.

Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.

This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.

Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/

MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2

Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #DMT #MNMD

California COWARDS Delay Psychedelics Decriminalization Bill (I’m Pissed)

California COWARDS Delay Psychedelics Decriminalization Bill (I’m Pissed)

Listen, Videos

What’s up psychedelic investors! Today’s episode is mostly a RANT about how the California cowards delayed the psychedelics decriminalization bill until NEXT YEAR, their reason being that their LEADERS ARE NOT “EDUCATED” enough on the matter at hand…😤

Enjoy my 11 minute rant!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#californiapsychedelicsbill #californiabill #psychedelicstocks

MORE Companies to UPLIST On NASDAQ? Compass Pathways Trial Results & More (CMPS, FTRP, MYCO, CYBN) 🚀

MORE Companies to UPLIST On NASDAQ? Compass Pathways Trial Results & More (CMPS, FTRP, MYCO, CYBN) 🚀

Listen, Videos

Compass Pathways (CMPS:NASDAQ) published amazing COMP360 Psilocybin Study results that will serve as support for companies working with psilocybin and psilocybin derivatives. However, this isn’t the only news worth mentioning.
Field Trip Health (FTRP: CSE) and (FTRPF: OTC) recently uplisted on the TSX ( Toronto Stock Exchange) and has filed an application to uplist on the Nasdaq.
While this is great news for Field Trip, it is not the only company who has filed to uplist. Silo Pharma, (SILO: OTC), has also put in an application to list on NASDAQ.
MagicMed will also join the ranks, however it will be through an acquisition.

Moreover, Cybin (CYBN: NEO,) and (CLXPF: OTC), is working on a transportable, wearable, helmet that completes a brain scan, through a partnership with a company called Kernel.
There is also news on Mydecine ( MYCO: NEO) and ( MYCOF: OTC) and MindCure (CSE: MCUR) (OTCQB: MCURF), so stay tuned till the end!

Enjoy the episode!

Timestamps:

0:00 – Intro
0:51 – Compass Pathways COMP360 Study Results
3:37 – Cybin Ketamine Study
7:14- Field Trip Uplists on the TSX And Applies To List On The NASDAQ
11:10 – Silo Pharma Applies To Uplist on The NASDAQ
12:11 – MagicMed to List On NASDAQ Through Acquisition
15:16- Mydecine Expands Cultivation Capabilities for Psilocybin
17:32- MINDCURE Completes First Stage of Manufacturing Synthetic Ibogaine

Links:
Compass Pathways Study Results On The Safety And Cognitive Effects Of Taking a Dose Of Psilocybin COMP360:
https://www.globenewswire.com/news-release/2021/06/03/2241445/0/en/COMPASS-Pathways-and-Kings-College-London-publish-cognition-results-from-COMP360-psilocybin-study-in-healthy-volunteers.html

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
https://psilocybinalpha.com/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics

Field Trip Health Uplists on the TSX:
https://www.globenewswire.com/news-release/2021/06/03/2241200/0/en/Field-Trip-Health-Ltd-to-Commence-Trading-on-the-Toronto-Stock-Exchange-on-June-7-2021.html

FTRP Applies To Uplist On NASDAQ:
https://stockhouse.com/news/the-market-herald-news/2021/06/08/field-trip-health-tsx-ftrp-applies-to-list-on-nasdaq-stock-market

MagicMed Will Be Acquired by Nasdaq-listed Enveric Biosciences
https://psilocybinalpha.com/news/magicmed-to-be-acquired-by-nasdaq-listed-company

Health Canada Has Approved an Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms MYCO: NEO), (MYCOF: OTC) :
https://finance.yahoo.com/news/health-canada-approves-expansion-mydecine-113000924.html

MINDCURE, (CSE: MCUR) (OTCQB: MCURF), Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research:
https://www.prnewswire.com/news-releases/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research-301304810.html

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #Mydecine #FieldTrip